All News

FDA releases draft guidance on the development of drugs to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia.

The Fogarty International Center, a component of the US NIH, calls for a focus on noncommunicable diseases and implementing science in low-resource settings.

WHO report provides a comprehensive picture of antibiotic resistance and suggests strategies to fight resistance.

AstraZeneca rejects $106 billion offer; Pfizer states its case for the merger with British government.

Gallus BioPharmaceuticals enters a cell line optimization and manufacturing agreement with Omni Bio Pharmaceutical.

USP releases new and revised standards for organic impurities in medicines for public comment.

Agenus and Merck work together to advance immune-oncology programs.

Allergy Therapeutics announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.

The European Medicines Agency's Annual Report highlights the agency's drug approvals, projects, and initiatives for 2013.

BMS acquisition of iPierian advances BMS' pursuit of therapeutics for genetically defined diseases.

TAP Biosystems announced that Gallus BioPharmaceuticals is using its ambr15 micro bioreactor system to optimize process development and clone selection of novel antibody therapeutics and biosimilars.

ISPE drug shortage prevention plan to address organizational strategies, manufacturing and quality systems, and supply chain quality.

Sartorius Stedim Biotech's acquisition of AllPure Technologies will extends its portfolio for single-use bioprocessing.

GE Healthcare and Promosome sign a licensing agreement that gives GE Healthcare exclusive rights to a new suite of mammalian cell line development technologies.

Spectrum Pharmaceuticals appoints Joseph Turgeon as president and COO.

Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.

Research reveals that proteins involved in autism interact with many more partners than previously known.

Portfolio swaps between Novartis and GSK involve oncology, vaccines, and consumer products.

University of Michigan study demonstrates how a Silly Putty ingredient could advance stem cell therapies.

Eli Lilly will acquire Novartis Animal Health for approximately $5.4 billion.

Genetic evidence supports role of APOBEC gene family in cancer development.

Lilly1s Cyramza is the first FDA-approved treatment for advanced gastric cancer after prior chemotherapy.

Aastrom Biosciences will acquire Sanofi's CTRM business for $6.5 million.

Novartis receives FDA breakthrough therapy designation for Bexsero, a meningitis B vaccine.

Immunovaccine's vaccine technology chosen for cervical, head, and neck cancer trials conducted by Dana-Farber Institute.

EMA notifies EU healthcare professionals of the falsified cancer drug Herceptin.

Mallinckrodt will acquire Questcor to create a diversified, high-growth specialty pharmaceuticals company.

CBER will move to the FDA White Oak campus in Silver Spring, Maryland.

A new report from PhRMA outlines potential growth trajectories affecting the biopharmaceutical industry.

ThioBridge linker technology to attach different payloads to a range of antibodies